Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.54 |
| ▸ | GSK3B | P49841 | 10/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | KCNB1 | Q14721 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716734 | 0.92 | ACACB (0.44) | MAPTGSK3BACACBFDPS | |
| SCHEMBL2716062 | 0.90 | GSK3B (0.43) | MAPTGSK3BACACBFDPS | |
| SCHEMBL2714246 | 0.89 | GSK3B (0.46) | MAPTGSK3BACACB | |
| SCHEMBL2715691 | 0.89 | SCN9A (0.42) | MAPTGSK3BSCN9AKCNB1ACACB | |
| SCHEMBL2716309 | 0.85 | MAPT (0.54) | MAPTGSK3BSCN9ARIOK2 | |
| SCHEMBL2716280 | 0.83 | MAPT (0.56) | MAPTGSK3BSCN9AACACBFDPS | |
| SCHEMBL15349998 | 0.82 | KCNB1 (0.48) | MAPTGSK3BKCNB1ACACBKCNA5 | |
| SCHEMBL2714780 | 0.82 | MAPT (0.55) | MAPTGSK3BSCN9AACACBFDPS | |
| SCHEMBL28396051 | 0.80 | KCNB1 (0.40) | MAPTGSK3BKCNB1KCNA5 | |
| SCHEMBL2719276 | 0.80 | RIPK1 (0.36) | SCN9AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | claimed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | claimed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | claimed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | claimed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | claimed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | MAPT 3185/4885GSK3B 4093/4885SCN9A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.